Novavax reported $430.32M in Debt for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Adamas Pharmaceuticals ADMS:US 4.17M 125.57M
Adma Biologics ADMA:US $ 93.88M 0.46M
Agenus AGEN:US $ 19.78M 0.59M
Astrazeneca AZN:US $ 27495M 7363M
AstraZeneca AZN:LN 27495M 7363M
Biocryst Pharmaceuticals BCRX:US $ 293.66M 9.32M
BioSpecifics Technologies BSTC:US 0 0
Dynavax Technologies DVAX:US $ 219.96M 40.07M
Genocea Biosciences GNCA:US $ 12M 0.19M
GlaxoSmithKline GSK:LN 25483M 736M
Kindred Biosciences KIN:US $ 19.87M 0.13M
Mannkind MNKD:US $ 285.13M 45.46M
Minerva Neurosciences NERV:US $ 0M 0M
Moderna Inc MRNA:US 487M 304M
Novartis NVS:US $ 35769M 2030M
Novavax NVAX:US $ 430.32M 29.91M
Pain Therapeutics PTIE:US $ 0M 0M
Peregrine Pharmaceuticals PPHM:US $ 138.81M 41.86M
Sarepta Therapeutics SRPT:US $ 1092.98M 1.88M